QPS is the main sponsor of the Analytical and Bioanalytical Day at the 7th World ADC Meeting, February 20 – 22, 2017 at the Maritim proArte Hotel in Berlin this week. Over 300 enthusiasts are expected to attend.
For all you assay aficionados out there, we thought you’d be juiced to know — we just added a whopping 47 new assays to the QPS Assay Finder Database (https://www.qps.com/ser-bioanalysis.php#QPSAssay)
At QPS, we love making customers happy. Here’s what two of them had to say about our work in DMPK protein binding studies:
First of all, my compliments and thanks for the work that Wenbin and the other members of the QPS team did on the XYZ protein binding study. Lots of samples, lots of work, lots of data. And all of it was handled very well and very quickly.
For outstanding performance including growth in sales, continuous growth in minority business to minority business purchases, innovation in the delivery of services, significant and continuous contribution to the growth and development of our community, and commitment to the cause and success of the EMSDC
, QPS has been named Class IV Supplier of the Year! The Awards Ceremony took place December 2, 2016 at the Hyatt at the Bellevue, in Philadelphia.
Mr. Sanjay Mitter joined QPS as VP and Global Head of Clinical Research Services. He is currently responsible for Clinical Research, i.e. global pharmacokinetics, data management, biostatistics, medical writing and publishing. He also oversees clinical monitoring and project management in the US.
Join us from July 24-27, 2016 in Toronto, Canada for the Alzheimer's Association International Conference.
QPS neuroscientists will attend the AAIC 2016 and would be pleased to meet you there at our booth#207
to discuss potential and ongoing projects.
Since 2012, a New Investigator Award has been given annually to honor excellence among bioanalytical scientists within their first five years in the industry. In this regard, Daniel Wilffert, a 2016 award nominee from QPS Netherlands, is truly fresh off the starting blocks. He started @QPS Holdings LLC last August and only just defended his thesis this past February at the University of Groningen.
We are exhibiting at the DIA 2016 Annual Meeting at our booth #1200 between June 26-30 at Philadelphia, PA, USA. If you are attending the meeting, please stop by to learn more about QPS’ Early Phase Clinical and Bioanalytical Services, including...
QPS CEO Ben Chien has made it through to the round of 30 (31, actually) being considered for this year’s prestigious EY Entrepreneur Of The Year Award
for the Greater Philadelphia area. The only competitive awards program in the world for entrepreneurs and leaders of high-growth companies, the 30 year-old program operates in 145 cities in 60 countries worldwide. Local winners may go on to receive national and potentially, worldwide recognition.
Each year, Life Science Leader
honors CROs that are the top performers in Compatibility, Capabilities, Expertise, Quality, and Reliability. To determine the winners, the magazine teams up with Industry Standard Research
(ISR). ISR looks at 27 different performance metrics, as rated by decision-making executives at biopharmaceutical companies.
Patient recruitment is one of the most critical foundations of any clinical trial. Effective patient recruitment sets the trial down a path toward success if done well, or can create a road full of potholes if managed incorrectly. On April 11th, Barbara Derler, PhD, heading the EU patient recruitment team from the QPS site in Austria spoke about successful enrollment activities at CTrials, The Israeli Association for the Advancement of the Biomedical Research Community.
QPS has been assisting an international Sponsor to perform a global, late-phase study to investigate the safety, efficacy, and pharmacokinetic behavior of an investigational drug in subjects with advanced prostate carcinoma.
Over the past 10 years, large molecule therapies have increased from 10% to nearly 50% of the typical pharma and biopharmaceutical pipeline. This transition has created new challenges in the industry.
QPS and Samsara Sciences
have solidified a cell supply partnership for the production, characterization and distribution of primary human liver cells including hepatocytes and hepatic stellate cells for research. QPS now has exclusive rights to distribute Samsara’s primary human hepatocytes. At the same time, the two companies will also cooperate to provide specialized non-parenchymal hepatocytes (NPCs) and assays. These offerings will be available in North America, Europe and Asia.
QPS will have a strong presence at ASCPT 2016 in San Diego March 9th-11th. Several members of QPS’ Early Phase Clinical team will be representing QPS’ 500 phase I clinical beds and full service clinical research services.
We are exhibiting at SOT 55th Annual Meeting and ToxExpoTM. Please visit our booth (#1813) between March 13-16 at the New Orleans Convention Center, New Orleans, LA, USA.
QPS has been assisting an international Sponsor to perform a global, late-phase study to investigate the safety, efficacy, and pharmacokinetic behavior of a newly formulated investigational drug in subjects with advanced prostate carcinoma.
If you need to quantify blood zinc levels, are working on a gadolinium-based MRI contrast agent, or need to measure platinum levels in mouse livers - a QPS-developed (LC)-ICP-MS assay may well be what you need.
Where do you turn when you just took the package? 25% of DuPont employees (likely more on the way) got the bad news here in Delaware, USA when DuPont merged with Dow Chemical in December. The state is hoping to stem the brain (and $) drain by encouraging these people to consider starting up new companies of their own which, in the past, has produced companies like W.L. Gore & Associates
. Enter this local news article about Ben Chien and QPS.
The role of Mg in human nutrition has recently received renewed interest. Mg dietary intake has been reported to have decreased during the last 100 years in Western countries. For example, in the US it is often below the recommended dietary allowances. Decreased Mg intake and/or low serum Mg have been associated with a number of major public health concerns such as type II diabetes, coronary heart disease, and osteoporosis.
On February 23, Professor Zuzana Diamant
, MD PhD, Director of Respiratory & Allergy Research at QPS, will talk about Biomarkers in Respiratory Drug Development and personalized medicine at the Informa-sponsored Early Clinical Development conference
, Amba Hotel Marble Arch, London.
Making the right decision about where to conduct Phase I of a clinical trial is crucial. As long as basic EU regulatory requirements are fulfilled, the investigational site may be located anywhere in the world.
Cancer immuno therapies. Oligo therapeutics. CAR T-cell therapies. Breakthrough Antivirals. For the past 20 years, we’ve been following the path of solid science and it’s lead us to this point: about to close out another year spent partnering with the world’s best pharmaceutical and biotech companies in pursuit of better solutions for patients.
LingSing Chen, PhD, former VP and Global Head of Translational Medicine and Biosimilars at QPS, shares her bioanalytical expertise in a new eBook published by Future Science's Bioanalysis Journal. The book — Bioanalysis for Biosimilars Development — went live this week.
The past 20 years for QPS have included countless hours of hard work, exciting change and a tireless commitment to do what is right for the client and the patient. Like anything, there have been ups and downs and challenges to overcome. There have also been accolades and—above all—a transcendent atmosphere of teamwork.
When I reflect on the past 20 years of my life, I remember both the milestones and the few challenges I encountered along the way. (Though, if I’m being completely honest it’s probably more than a few, many of them self-inflicted, but who’s keeping score?)
Come review and discuss the latest xenobiotic research with us in person. Top QPS scientists will be at the 20th North American ISSX Meeting next week in Orlando, Florida, where they'll display three posters with contributions from QPS. We're looking forward to answering your questions and hearing your thoughts about our findings. The posters below will be on display in the Exhibit Hall (Bonnet Creek I – IX) at the Hilton Orlando Bonnet Creek Resort, Monday, Oct. 19 through Wednesday, Oct. 21. See you soon!
When Ben Chien
, PhD, QPS Chairman, President and CEO, first started a small bioanalytical lab with just three people, he wasn’t expecting it to grow into a worldwide CRO with more than 1,150 employees.
Brandi Muehlethaler, Supervisor Wet Lab Operations, says she still gets emotional thinking about the role she had in developing a drug therapy for stroke victims that ended up helping her own father. And Brandi’s not alone at QPS in her knowledge of how important her work is to patients.
As anyone with fond memories of home cooked meals knows, the best food you can find isn’t determined only by the ingredients, or the recipe or how perfect the chef’s technique is. The very best food - the meals you remember and keep going back for - have a little something extra: love. Many think you can taste the difference when a chef truly loves what they do and cares about the people they are serving. And call us sentimental, but we think the same is true of our work here at QPS.
This year QPS marks 20 years as a leading CRO serving our clients in pharma R&D navigation. To celebrate, we're taking a moment to reintroduce ourselves to you: who we are, what we do and where we're going.
The focus of this seminar is on increasing the success of Biotech. Participation is free of charge.
CEO Award an indicator of company-wide hard work and inspiration
QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, has been selected to receive a 2015 Finance Monthly magazine CEO Award. To view this year’s winners....
It’s time to register for the Hepatocyte Research Association (HRA) 11th Annual Meeting at ISSX Orlando...
QPS was able to deliver on this extremely challenging early phase clinical trial because we have access to the expertise of a university anaesthesiology department in the Netherlands, and its associated facilities.
Okay, we’ll admit it: a company telling you about their new brochure seems about as interesting as looking through your Great Uncle’s vacation pictures - for the tenth time. But we can’t help it. We’re really excited about this one! That’s because we’re proud to provide specialized, collaborative Clinical Development services that help us build relationships with our clients that last throughout the entire drug development process.
Ever wish that really big hill you always cycle up would seem a little less hilly? Want to swing impressive poundage at your next kettlebell class?According to Doug Kalman PhD, RD, Director of Nutrition & Endocrinology at QPS MRA (Miami Research Associates) and other contributors to the International Society of Sports Nutrition’s position paper on β-Alanine, you can!
Cannabinoid bioscience has come a long way. New York-based Axim Biotech is at the forefront, developing - among many other, related products - a multi-layered, slow-release cannabinoid chewing gum.
Need a vacation? Don’t have time? Spend the next 45 seconds pretending you’re here
Finding something tasty to drink at the mini-mart has gotten really complicated lately. Knowing the usual soft drinks are unhealthy, you may be tempted by the “sport” drink section. But even if you’ve grabbed the colorless option to avoid massive quantities of Blue #1 or Yellow #5, a quick label-read may have you flipping that bottle back on the shelf in despair. And the rest of the case holds legions of equally dubious products.
Launch of two-month public consultations on revised guidelines on accelerated assessment and conditional marketing authorization.
Cabozantinib (COMETRIQ®) inhibits the activity of tyrosine kinases including MET, VEGFRs and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.
The sheer abundance of diet drugs available suggests two things: 1) there is a huge market for them and 2) none of them work significantly better than the rest (if at all.) Imagine the excitement, then, at finding that an agent already prescribed for diabetes really can help patients lose significant amounts of weight. And QPS MRA’s own Dr. Krieger had a hand in developing the results!
What were they talking about? As you undoubtedly realize, LBA (Ligand Binding Assay) is the current accepted gold standard for the quantitative measurement of biologics. But once mass spectrometry (LC-MS/MS) has been proven to perform complementary to LBA (and trust us, it “is”!), this next-generation assay technique is destined to become another gold standard.
In July 2015, regulatory expert Patricia Baede joined QPS’ clinical development teams. With 20 years of experience in clinical trial conduct and all regulatory aspects of drug development, Baede adds EU regulatory support to the growing portfolio of clinical activities QPS provides. In the past, she has worked on drug development teams as Phase I Clinical Trial Expert and as Phase II and Phase III Regulatory Expert.